Pharmacoeconomics in heart failure: Impact of drug and non-drug based treatment

European Heart Journal, Supplement

Volumn 3, Issue G, 2001, Pages

  Cleland, J G F ^a   Louis, A ^a   Witte, K ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

Author keywords

Clinical outcome; Diuretics; Furosemide; Heart failure; Pharmacoeconomics; Torasemide

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOOP DIURETIC AGENT; SPIRONOLACTONE; TORASEMIDE;

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG COST; HEALTH CARE COST; HEART FAILURE; HOSPITALIZATION; HUMAN; MORBIDITY; MORTALITY; OUTPATIENT; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT PLANNING;

EID: 0034883966     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0195-668x(01)80005-1     Document Type: Conference Paper

References (32)

1. The heart failure epidemic: Exactly how big is it?
2. Clinical trials update. IMPROVEMENT-HF, COPERNICUS, MUSTIC, ASPECT-II and APRICOT
3. Is the prognosis of heart failure improving?
4. Guidelines for the diagnosis of heart failure
5. The epidemiology of heart failure
6. Screening for left ventricular dysfunction and chronic heart failure: Should it be done and, if so, how
7. Influence of concomitant disease on patterns of hospitalisation in patients with heart failure discharged from Scottish hospitals in 1995
8. Evolving trends in the epidemiology factors of heart failure: Rationale for preventive strategies and comprehensive disease management
9. Economic impact of heart failure in the United States: Time for a different approach
10. Trends in hospitalization for heart failure in Scotland 1980-1990
11. Is the prognosis of heart failure improving?
12. Prognosis of heart failure - A population based study of the outcome in incident cases
13. Clinical epidemiology of heart failure: Public and private health care burden
14. Successes and failures of current treatment of heart failure
15. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study
16. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
17. The evidence for beta-blockers equals or surpasses that for ACE inhibitors in heart failure
18. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
19. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
20. Effects of controlled-release metoprolol on total mortality, hospitalization, and well-being in patients with heart failure: The metoprolol CR-XL randomized intervention trial in congestive heart failure (MERIT-HF)
21. Low doses vs high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: A cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study
22. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
23. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II)
24. Health economic consequences of the pharmacological treatment of heart failure
25. Diuretic Therapy
26. A pharmacoeconomic assessment of torsemide and furosemide in the treatment of patients with congestive heart failure
27. Determining the effectiveness of torasemide and furosemide in heart failure: Design of a randomised comparison using the Regenstrief medical record system
28. Healthcare costs of patients with heart failure treated with torasemide or furosemide
29. A pharmacoeconomic assessment of torsemide in the treatment of congestive heart failure
30. Improved prognosis of patients with chronic heart failure by an optimized diuretic therapy with the new loop diuretic torasemide
31. Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint
32. Effects of type of diuretic on mortality in patients with chronic congestive heart failure